Seeking Alpha

Dynavax rises in morning trading

  • Dynavax Technologies (DVAX +8.4%) posts solid gains in morning trading.
  • The company said Tuesday evening that immunogenicity and safety results from two Phase 3 Heplisav trials were published in Vaccine along with some commentary by two doctors.
  • Long story short, here's what was said: These two trials are further evidence that the adjuvant in Heplisav is "important" in hepatitis B immunization. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: